19.08.2022 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius


 

DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Personnel
Fresenius SE & Co. KGaA: Michael Sen to succeed Stephan Sturm as CEO of Fresenius

19-Aug-2022 / 18:33 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Michael Sen to succeed Stephan Sturm as CEO of Fresenius

Michael Sen (53) will become Chief Executive Officer of Fresenius on October 1, 2022. He was appointed unanimously by the Supervisory Board of Fresenius Management SE today to succeed Stephan Sturm (59), who will leave the company on good terms on September 30. Michael Sen will, in addition, continue to serve as CEO of Fresenius Kabi until a successor is decided for this position.

Michael Sen has been responsible for the Fresenius Kabi business segment on the Fresenius Management Board since April 2021. Previously, he was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. From 2015 to 2017 he was Chief Financial Officer of E.ON SE.

Stephan Sturm has been a member of the Fresenius Management Board since 2005, beginning as CFO. He became CEO of Fresenius on July 1, 2016.

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., August 19, 2022

----------------------------------------

Contact:

Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
[email protected]

----------------------------------------

 

End of Note


19-Aug-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: [email protected]
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1424637

 
End of Announcement DGAP News Service

1424637  19-Aug-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1424637&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 40.840,00 22.299,00
EBITDA1,2 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 6.808,00 3.422,00
EBITDA-Marge3 18,69 17,04 19,01 19,66 18,27 16,67
EBIT1,4 4.589,00 5.251,00 4.631,00 4.385,00 4.158,00 3.321,00 1.143,00
EBIT-Marge5 13,69 14,83 12,43 12,09 11,08 8,13 5,13
Jahresüberschuss1 1.816,00 1.871,00 1.915,00 2.823,00 2.819,00 2.117,00 -594,00
Netto-Marge6 5,42 5,28 5,14 7,78 7,51 5,18 -2,66
Cashflow1,7 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 4.198,00 4.456,00
Ergebnis je Aktie8 3,25 3,37 3,44 3,06 3,26 2,44 -1,05
Dividende8 0,75 0,80 0,84 0,88 0,92 0,92 0,62
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 27,180 Halten 15.308,79
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,07 16,61 0,79 10,94
KBV KCV KUV EV/EBITDA
0,81 3,44 0,69 8,35
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,92 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 31.07.2024 06.11.2024 20.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,86% -0,06% -3,17% 5,76%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE